<?xml version="1.0" encoding="UTF-8"?>
<lom xmlns="http://ltsc.ieee.org/xsd/LOM" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://ltsc.ieee.org/xsd/LOM http://standards.ieee.org/reading/ieee/downloads/LOM/lomv1.0/xsd/lom.xsd">
<general>
<title>
<string language="el">Rational design, efficient syntheses and biological evaluation of N,N′-symmetrically bis-substituted butylimidazole analogs as a new class of potent Angiotensin II receptor blockers</string>
</title>
<language>eng</language>
<identifier>
<catalog>URI</catalog>
<entry>http://hdl.handle.net/10795/3345</entry>
</identifier>
<subject>
<string language="el">φυσικές επιστήμες</string>
<string language="el">χημεία</string>
<string language="el">ιατρικές επιστήμες</string>
<string language="el">ασθένεια του νευρικού συστήματος</string>
<string language="el">προσομοίωση</string>
<string language="el">φαρμακευτική</string>
</subject>
<description>
<string language="el">A series of symmetrically bis-substituted imidazole analogs bearing at the N-1 and N-3 two biphenyl moieties ortho substituted either with tetrazole or carboxylate functional groups was designed based on docking studies and utilizing for the first time an extra hydrophobic binding cleft of AT1 receptor. The synthesized analogs were evaluated for their in vitro antagonistic activities (pA2 values) and binding affinities (–logIC50 values) to the Angiotensin II AT1 receptor. Among them, the potassium (–logIC50 = 9.04) and the sodium (–logIC50 = 8.54) salts of 4-butyl-N,N′-bis{[2′-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}imidazolium bromide (12a and 12b, respectively) as well as its free acid 11 (–logIC50 = 9.46) and the 4-butyl-2-hydroxymethyl-N,N′-bis{[2′-(2H-tetrazol-5-yl)biphenyl-4-yl]methyl}imidazolium bromide (14) (–logIC50 = 8.37, pA2 = 8.58) showed high binding affinity to the AT1 receptor and high antagonistic activity (potency). The potency was similar or even superior to that of Losartan (–logIC50 = 8.25, pA2 = 8.25). On the contrary, 2-butyl-N,N′-bis{[2′-[2H-tetrazol-5-yl)]biphenyl-4-yl]methyl}imidazolium bromide (27) (–logIC50 = 5.77) and 2-butyl-4-chloro-5-hydroxymethyl-N,N′-bis{[2′-[2H-tetrazol-5-yl)]biphenyl-4-yl]methyl}imidazolium bromide (30) (–logIC50 = 6.38) displayed very low binding affinity indicating that the orientation of the n-butyl group is of primary importance. Docking studies of the representative highly active 12b clearly showed that this molecule has an extra hydrophobic binding feature compared to prototype drug Losartan and it fits to the extra hydrophobic cavity. These results may contribute to the discovery and development of a new class of biologically active molecules through bis-alkylation of the imidazole ring by a convenient and cost effective synthetic strategy.</string>
</description>
<description>
<string language="el">19 pp.</string>
</description>
</general>
<lifecCycle>
<contribute>
<source>LOMv1.0</source>
<value>creator</value>
<entity><![CDATA[BEGIN:VCARD
FN: Agelis, George
N: Agelis, George
"VERSION:3.0"
END:VCARD]]></entity>
</contribute>
<contribute>
<source>LOMv1.0</source>
<value>publisher</value>
<entity><![CDATA[BEGIN:VCARD
FN: ELSEVIER
N: ELSEVIER
"VERSION:3.0"
END:VCARD]]></entity>
<contribute>
<contribute>
<source>LOMv1.0</source>
<value>Scientific Coordinator</value>
<entity><![CDATA[BEGIN:VCARD
FN: Μαυρομούστακος, Θωμάς
N: Μαυρομούστακος, Θωμάς
"VERSION:3.0"
END:VCARD]]></entity>
</contribute>
<contribute>
<source>LOMv1.0</source>
<value>Project Executing Organisation</value>
<entity><![CDATA[BEGIN:VCARD
FN: Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)
N: Εθνικό και Καποδιστριακό Πανεπιστήμιο Αθηνών (ΕΚΠΑ)
"VERSION:3.0"
END:VCARD]]></entity>
</contribute>
<date>
<dateStamp>2013-01-02</dateStamp>
</date>
</lifecCycle>
<educational>
<learningResourceType>
<source>Digital Library of the Operational Programme "Education and Lifelong Learning" abstract types</source>
<value>Text</value>
</learningResourceType>
</educational><classification><keyword>
<string language="el">AT1 receptor blockers</string>
</keyword>
<keyword>
<string language="el">N,N′-Bis-alkylated butylimidazole analogs</string>
</keyword>
<keyword>
<string language="el">Synthesis</string>
</keyword>
<keyword>
<string language="el">Wittig reaction</string>
</keyword>
<keyword>
<string language="el">Hydroxymethylation</string>
</keyword>
<keyword>
<string language="el">Structure elucidation</string>
</keyword>
<keyword>
<string language="el">Docking studies</string>
</keyword>
<keyword>
<string language="el">Molecular dynamics</string>
</keyword>
<keyword>
<string language="el">Biological evaluation</string>
</keyword>
</classification>
<technical>
</technical>
<technical>
<size>1983417</size>
<format>application/pdf</format>
<location>http://repository.edulll.gr/edulll/bitstream/10795/3345/2/3345_1.153_%ce%94%ce%97%ce%9c_2_1_13.pdf</location>
</technical>
<annotation></annotation><metaMetadata><identifier>
<catalog>URI</catalog>
<entry>http://hdl.handle.net/10795/3345</entry>
</identifier>
<contribute>
<entity><![CDATA[BEGIN:VCARD
FN:National Documentation Centre - National Hellenic Research Foundation
N:National Documentation Centre - National Hellenic Research Foundation
"VERSION:3.0"
END:VCARD]]></entity>
<role><source>LOMv1.0</source><value>creator</value></role>
<date><dateTime>2016-05-23T11:49:11Z</dateTime></date>
</contribute>
<contribute>
<entity><![CDATA[BEGIN:VCARD
FN:National Documentation Centre - National Hellenic Research Foundation
N:National Documentation Centre - National Hellenic Research Foundation
"VERSION:3.0"
END:VCARD]]></entity>
<role><source>LOMv1.0</source><value>validator</value></role>
<date><dateTime>2016-05-23T11:49:11Z</dateTime></date>
</contribute>
<metadataSchema>LOMv1.0</metadataSchema>
<language>gre</language>
</metaMetadata>
<rights>
<cost>no</cost>
<copyright>no</copyright>
<description>Copyright EYD-EPEDBM (Operational Programme "Education and Lifelong Learning")</description>
</rights>
</lom>